ArticleAdvanced drug delivery reviews2011
Hybrid magnetic nanostructures (MNS) for magnetic resonance imaging applications.
Article in Advanced drug delivery reviews, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Targeting breast cancer: the promise of phage-based nanomedicines.Breast cancer research and treatment · 2025Review
- Multifunctional Superparamagnetic Iron Oxide Nanoparticles Conjugated with Aβ Oligomer-Specific scFv Antibody and Class A Scavenger Receptor Activator Show Early Diagnostic Potentials for Alzheimer's Disease.International journal of nanomedicine · 2020Article
- Uniform FeBeilstein journal of nanotechnology · 2020Article
- Application of Iron Oxide Nanoparticles in the Diagnosis and Treatment of Neurodegenerative Diseases With Emphasis on Alzheimer's Disease.Frontiers in cellular neuroscience · 2020Review
- Enabling biodegradable functional biomaterials for the management of neurological disorders.Advanced drug delivery reviews · 2019Review
- Iron Oxide Colloidal Nanoclusters as Theranostic Vehicles and Their Interactions at the Cellular Level.Nanomaterials (Basel, Switzerland) · 2018Article
- Positron emission tomography and nanotechnology: A dynamic duo for cancer theranostics.Advanced drug delivery reviews · 2017Review
- Lipid-coated iron oxide nanoparticles for dual-modal imaging of hepatocellular carcinoma.International journal of nanomedicine · 2017Article
- Theranostic Magnetic Nanostructures (MNS) for Cancer.Cancer treatment and research · 2015Review
- Towards non-invasive diagnostic imaging of early-stage Alzheimer's disease.Nature nanotechnology · 2015Article
- Thermoresponsive magnetic hydrogels as theranostic nanoconstructs.ACS applied materials & interfaces · 2014Article
- TJournal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology · 2014Article
- Nanoparticle-based systems for T(1)-weighted magnetic resonance imaging contrast agents.International journal of molecular sciences · 2013Review
- Molecular brain imaging in the multimodality era.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The development of MRI contrast agents has experienced its version of the gilded age over the past decade, thanks largely to the rapid advances in nanotechnology. In addition to progress in single mode contrast agents, which ushered in unprecedented R(1) or R(2) sensitivities, there has also been a boon in the development of agents covering more than one mode of detection. These include T(1)-PET, T(2)-PET T(1)-optical, T(2)-optical, T(1)-T(2) agents and many others. In this review, we describe four areas which we feel have experienced particular growth due to nanotechnology, specifically T(2) magnetic nanostructure development, T(1)/T(2)-optical dual mode agents, and most recently the T(1)-T(2) hybrid imaging systems. In each of these systems, we describe applications including in vitro, in vivo usage and assay development. In all, while the benefits and drawbacks of most MRI contrast agents depend on the application at hand, the recent development in multimodal nanohybrids may curtail the shortcomings of single mode agents in diagnostic and clinical settings by synergistically incorporating functionality. It is hoped that as nanotechnology advances over the next decade, it will produce agents with increased diagnostics and assay relevant capabilities in streamlined packages that can meaningfully improve patient care and prognostics. In this review article, we focus on T(2) materials, its surface functionalization and coupling with optical and/or T(1) agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.